Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche

Abstract Bone metastasis is a major cause of cancer death; however, the epigenetic determinants driving this process remain elusive. Here, we report that histone methyltransferase ASH1L is genetically amplified and is required for bone metastasis in men with prostate cancer. ASH1L rewires histone me...

Full description

Saved in:
Bibliographic Details
Main Authors: Chenling Meng, Kevin Lin, Wei Shi, Hongqi Teng, Xinhai Wan, Anna DeBruine, Yin Wang, Xin Liang, Javier Leo, Feiyu Chen, Qianlin Gu, Jie Zhang, Vivien Van, Kiersten L. Maldonado, Boyi Gan, Li Ma, Yue Lu, Di Zhao
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-59381-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850141460306853888
author Chenling Meng
Kevin Lin
Wei Shi
Hongqi Teng
Xinhai Wan
Anna DeBruine
Yin Wang
Xin Liang
Javier Leo
Feiyu Chen
Qianlin Gu
Jie Zhang
Vivien Van
Kiersten L. Maldonado
Boyi Gan
Li Ma
Yue Lu
Di Zhao
author_facet Chenling Meng
Kevin Lin
Wei Shi
Hongqi Teng
Xinhai Wan
Anna DeBruine
Yin Wang
Xin Liang
Javier Leo
Feiyu Chen
Qianlin Gu
Jie Zhang
Vivien Van
Kiersten L. Maldonado
Boyi Gan
Li Ma
Yue Lu
Di Zhao
author_sort Chenling Meng
collection DOAJ
description Abstract Bone metastasis is a major cause of cancer death; however, the epigenetic determinants driving this process remain elusive. Here, we report that histone methyltransferase ASH1L is genetically amplified and is required for bone metastasis in men with prostate cancer. ASH1L rewires histone methylations and cooperates with HIF-1α to induce pro-metastatic transcriptome in invading cancer cells, resulting in monocyte differentiation into lipid-associated macrophage (LA-TAM) and enhancing their pro-tumoral phenotype in the metastatic bone niche. We identified IGF-2 as a direct target of ASH1L/HIF-1α and mediates LA-TAMs’ differentiation and phenotypic changes by reprogramming oxidative phosphorylation. Pharmacologic inhibition of the ASH1L-HIF-1α-macrophages axis elicits robust anti-metastasis responses in preclinical models. Our study demonstrates epigenetic alterations in cancer cells reprogram metabolism and features of myeloid components, facilitating metastatic outgrowth. It establishes ASH1L as an epigenetic driver priming metastasis and macrophage plasticity in the bone niche, providing a bona fide therapeutic target in metastatic malignancies.
format Article
id doaj-art-e046c7323e32427aa63a71604b974d44
institution OA Journals
issn 2041-1723
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-e046c7323e32427aa63a71604b974d442025-08-20T02:29:26ZengNature PortfolioNature Communications2041-17232025-05-0116112310.1038/s41467-025-59381-2Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone nicheChenling Meng0Kevin Lin1Wei Shi2Hongqi Teng3Xinhai Wan4Anna DeBruine5Yin Wang6Xin Liang7Javier Leo8Feiyu Chen9Qianlin Gu10Jie Zhang11Vivien Van12Kiersten L. Maldonado13Boyi Gan14Li Ma15Yue Lu16Di Zhao17Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Imaging Physics, The University of Texas MD Anderson Cancer CenterDepartment of Imaging Physics, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer CenterAbstract Bone metastasis is a major cause of cancer death; however, the epigenetic determinants driving this process remain elusive. Here, we report that histone methyltransferase ASH1L is genetically amplified and is required for bone metastasis in men with prostate cancer. ASH1L rewires histone methylations and cooperates with HIF-1α to induce pro-metastatic transcriptome in invading cancer cells, resulting in monocyte differentiation into lipid-associated macrophage (LA-TAM) and enhancing their pro-tumoral phenotype in the metastatic bone niche. We identified IGF-2 as a direct target of ASH1L/HIF-1α and mediates LA-TAMs’ differentiation and phenotypic changes by reprogramming oxidative phosphorylation. Pharmacologic inhibition of the ASH1L-HIF-1α-macrophages axis elicits robust anti-metastasis responses in preclinical models. Our study demonstrates epigenetic alterations in cancer cells reprogram metabolism and features of myeloid components, facilitating metastatic outgrowth. It establishes ASH1L as an epigenetic driver priming metastasis and macrophage plasticity in the bone niche, providing a bona fide therapeutic target in metastatic malignancies.https://doi.org/10.1038/s41467-025-59381-2
spellingShingle Chenling Meng
Kevin Lin
Wei Shi
Hongqi Teng
Xinhai Wan
Anna DeBruine
Yin Wang
Xin Liang
Javier Leo
Feiyu Chen
Qianlin Gu
Jie Zhang
Vivien Van
Kiersten L. Maldonado
Boyi Gan
Li Ma
Yue Lu
Di Zhao
Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche
Nature Communications
title Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche
title_full Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche
title_fullStr Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche
title_full_unstemmed Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche
title_short Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche
title_sort histone methyltransferase ash1l primes metastases and metabolic reprogramming of macrophages in the bone niche
url https://doi.org/10.1038/s41467-025-59381-2
work_keys_str_mv AT chenlingmeng histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT kevinlin histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT weishi histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT hongqiteng histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT xinhaiwan histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT annadebruine histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT yinwang histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT xinliang histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT javierleo histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT feiyuchen histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT qianlingu histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT jiezhang histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT vivienvan histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT kierstenlmaldonado histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT boyigan histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT lima histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT yuelu histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche
AT dizhao histonemethyltransferaseash1lprimesmetastasesandmetabolicreprogrammingofmacrophagesintheboneniche